Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) Products under Development by Stage of Development | 7 | 1 |
| Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) Products under Development by Therapy Area | 8 | 1 |
| Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) Products under Development by Indication | 9 | 1 |
| Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) Products under Development by Companies | 12 | 2 |
| Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) Therapeutics Assessment | 14 | 7 |
| Assessment by Monotherapy/Combination Products | 14 | 1 |
| Assessment by Mechanism of Action | 15 | 2 |
| Assessment by Route of Administration | 17 | 2 |
| Assessment by Molecule Type | 19 | 2 |
| Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) Companies Involved in Therapeutics Development | 21 | 6 |
| Abeona Therapeutics, Inc. | 21 | 1 |
| Alexion Pharmaceuticals, Inc. | 22 | 1 |
| BioMarin Pharmaceutical Inc. | 23 | 1 |
| Dorphan S.A. | 24 | 1 |
| Laboratorios Del Dr. Esteve S.A. | 25 | 1 |
| UniQure N.V. | 26 | 1 |
| Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) Drug Profiles | 27 | 12 |
| ABO-101 Drug Profile | 27 | 2 |
| AMT-110 Drug Profile | 29 | 2 |
| BMN-250 Drug Profile | 31 | 2 |
| EGT-201 Drug Profile | 33 | 1 |
| SBC-103 Drug Profile | 34 | 3 |
| Small Molecule to Target Alpha-N-Acetylglucosaminidase for MPSIIIB Drug Profile | 37 | 1 |
| Stem Cell Therapy to Activate NAG for Mucopolysaccharidosis III Drug Profile | 38 | 1 |
| Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) Dormant Projects | 39 | 1 |
| Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) Featured News &Press Releases | 40 | 13 |
| May 24, 2016: Abeona Therapeutics Announces FDA Allowance of Investigational New Drug for Phase 1/2 Clinical Study With ABO-101 Gene Therapy for Patients With Sanfilippo Syndrome Type B (MPS IIIB) | 40 | 1 |
| Apr 21, 2016: BioMarin Enrolls First Patient in Phase 1/2 Trial of NAGLU Fusion Protein BMN 250 for Treatment of MPS IIIB (Sanfilippo B Syndrome) | 41 | 1 |
| Mar 01, 2016: SBC-103 (rhNAGLU enzyme) Shows a 26.2 Percent Mean Reduction in Heparan Sulfate in Cerebrospinal Fluid at the Highest Dose Studied in Patients with Mucopolysaccharidosis IIIB in Phase 1/2 Study at Six Months | 42 | 1 |
| Feb 25, 2016: ESTEVE Provides Update On EGT-201 For Sanfilippo B Syndrome | 43 | 1 |
| Jan 11, 2016: Abeona Therapeutics Announces Initial European Regulatory Approval for Phase 1/2 Gene Therapy Clinical Study for Patients With Sanfilippo Syndrome | 43 | 1 |
| Sep 19, 2015: Positive Topline Results Announced From Phase I/II Trial in Sanfilippo B Syndrome Patients Using uniQure's Novel AAV5-Based Gene Therapy | 44 | 1 |
| Jun 04, 2015: Synageva BioPharma Completes Targeted Enrollment in Phase 1/2 Trial with SBC-103 for Mucopolysaccharidosis IIIB | 45 | 1 |
| May 20, 2015: PlasmaTech Biopharmaceuticals Announces Orphan Drug and Rare Pediatric Disease Designations For ABX-101 From FDA | 46 | 1 |
| Jan 26, 2015: Synageva BioPharma Announces Dosing Of Patients Commenced With SBC-103 In Phase 1/2 Study For Mucopolysaccharidosis IIIB And FDA Fast Track Designation Granted | 46 | 1 |
| Dec 15, 2014: Synageva BioPharma Announces Active Investigational New Drug Application For SBC-103 For The Treatment Of Mucopolysaccharidosis IIIB | 47 | 1 |
| Dec 10, 2014: FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion Protein, BMN 250, for the Treatment of MPS IIIB (Sanfilippo Syndrome Type B) | 48 | 1 |
| Feb 12, 2014: Synageva BioPharma Highlights SBC-103 Data at the Lysosomal Disease Network WORLD Symposium | 48 | 2 |
| Feb 11, 2014: BioMarin Announces Selection of NAGLU Fusion Protein Drug Development Candidate BMN 250 for the Treatment of Sanfilippo B | 50 | 1 |
| Jan 29, 2014: Synageva BioPharma Announces Data Presentations On SBC-103 at the 10th Annual Lysosomal Disease Network World Symposium | 51 | 1 |
| Jan 30, 2013: Synageva BioPharma To Present Scientific Data On SBC-103 At 9th Annual LDN WORLD Symposium | 52 | 1 |
| Appendix | 53 | 2 |
| Methodology | 53 | 1 |
| Coverage | 53 | 1 |
| Secondary Research | 53 | 1 |
| Primary Research | 53 | 1 |
| Expert Panel Validation | 53 | 1 |
| Contact Us | 53 | 1 |
| Disclaimer | 54 | 1 |